Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Affect lability, Asthenia, Cognitive disorder, Discomfort, Fatigue
Clinical narrative: Weakness; Emotional lability; Fuzzy thinking and memory; Cognitive symptoms; Fatigue; Body peeling all over; Delayed vaccine reaction moderate-severe; Extremely uncomfortable, face, chest extremely uncomfortable systemically; Red rash; Fever; Left arm is inflamed; Rashes down the chest and large portion of the body/ severe rash head to toe, Ghot red raised rash; This spontaneous case was reported by a consumer and describes the occurrence of INFLAMMATION (Left arm is inflamed), DISCOMFORT (Extremely uncomfortable, face, chest extremely uncomfortable systemically), ASTHENIA (Weakness), AFFECT LABILITY (Emotional lability) and MEMORY IMPAIRMENT (Fuzzy thinking and memory) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010M20A and 011L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Blood pressure high (Increased medication last couple of years) since 2007, High cholesterol (Started medication 6 months ago) since 2007, CPAP (Improving, very mild.), Drug allergy (NOS), Food allergy (Macadamia Nuts allergy), Drug allergy (Codeine derivatives allergy) and Allergy to vaccine (Moderna COVID vaccine). Concomitant products included VALSARTAN and DILTIAZEM for Blood pressure high, ATORVASTATIN for High cholesterol, FLUOXETINE HYDROCHLORIDE (FLUOXETIN), ESTRADIOL (ESTROGEN), PROGESTERONE and TESTOSTERONE for Menopause.   On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 07-Feb-2021, the patient experienced INFLAMMATION (Left arm is inflamed) and RASH (Rashes down the chest and large portion of the body/ severe rash head to toe, Ghot red raised rash). On 08-Feb-2021, the patient experienced DISCOMFORT (Extremely uncomfortable, face, chest extremely uncomfortable systemically), RASH ERYTHEMATOUS (Red rash) and PYREXIA (Fever). On 15-Feb-2021, the patient experienced SKIN REACTION (Delayed vaccine reaction moderate-severe). On 11-Mar-2021, the patient experienced SKIN EXFOLIATION (Body peeling all over). On an unknown date, the patient experienced ASTHENIA (Weakness), AFFECT LABILITY (Emotional lability), MEMORY IMPAIRMENT (Fuzzy thinking and memory), COGNITIVE DISORDER (Cognitive symptoms) and FATIGUE (Fatigue). The patient was treated with PREDNISONE (PREDNISON) for Rash and Fever, at an unspecified dose and frequency; LORATADINE, PSEUDOEPHEDRINE HYDROCHLORIDE (BENADRYL 24 D) for Adverse event, at an unspecified dose and frequency and CETIRIZINE HYDROCHLORIDE (ZYRTEC ALLERGY) for Adverse event, at an unspecified dose and frequency. In April 2021, INFLAMMATION (Left arm is inflamed) had resolved. At the time of the report, DISCOMFORT (Extremely uncomfortable, face, chest extremely uncomfortable systemically), ASTHENIA (Weakness), AFFECT LABILITY (Emotional lability), MEMORY IMPAIRMENT (Fuzzy thinking and memory) and SKIN EXFOLIATION (Body peeling all over) had resolved with sequelae, RASH ERYTHEMATOUS (Red rash), COGNITIVE DISORDER (Cognitive symptoms), RASH (Rashes down the chest and large portion of the body/ severe rash head to toe, Ghot red raised rash), PYREXIA (Fever) and FATIGUE (Fatigue) had resolved and SKIN REACTION (Delayed vaccine reaction moderate-severe) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medications included unspecified intravenous steroids and prednisone.   This case was linked to MOD-2021-033224 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Jul-2021: Follow up received on 14-JUL-2021. New events, Patient demographics (height and weight), race & ethinicity, new reporter's information, medical history, concomitant medication and second dose details were added. On 14-Jul-2021: Non-significant follow-up appended On 20-Jul-2021: Contains no new information.